NeuraxisNRXS
NRXS
About: Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
Employees: 19
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
156% more capital invested
Capital invested by funds: $308K [Q2] → $790K (+$481K) [Q3]
2.07% more ownership
Funds ownership: 1.67% [Q2] → 3.73% (+2.07%) [Q3]
10% less funds holding
Funds holding: 10 [Q2] → 9 (-1) [Q3]
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Research analyst outlook
We haven’t received any recent analyst ratings for NRXS.
Financial journalist opinion
Neutral
Seeking Alpha
1 month ago
NeurAxis, Inc (NRXS) Q3 2024 Earnings Call Transcript
NeurAxis, Inc (NYSE:NRXS ) Q3 2024 Results Conference Call November 12, 2024 9:00 AM ET Company Participants Ben Shamsian - Investor Relations Brian Carrico - Chief Executive Officer Tim Henrichs - Chief Financial Officer Operator Good day, and thank you for standing by. Welcome to the NeurAxis's Third Quarter 2024 Financial Results Conference Call.
Positive
Zacks Investment Research
1 month ago
NeurAxis Stock Surges After Strong Q3 Earnings and Expanded Coverage
NRXS reports strong third-quarter results with rising revenues, reduced losses and expanded insurance coverage, driving its stock to outperform the market.
Neutral
GlobeNewsWire
1 month ago
NeurAxis Reports Strong Third Quarter 2024 Financial Results Driven by a 40% Increase in Revenues
Conference call will be held today, Tuesday, November 12 at 9:00 am ET Conference call will be held today, Tuesday, November 12 at 9:00 am ET
Neutral
GlobeNewsWire
1 month ago
NeurAxis Announces New CPT® Category I Code for Percutaneous Electrical Nerve Field Stimulation
CARMEL, Ind., Oct. 22, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, announced that the American Medical Association (AMA) has established a new Current Procedural Terminology (CPT) Category I code for Percutaneous Electrical Nerve Field Stimulation (PENFS) procedures effective January 1, 2026.
Neutral
Zacks Investment Research
2 months ago
Zacks Initiates Coverage of NeurAxis With Neutral Recommendation
Discover why Zacks rates NeurAxis as "Neutral", being the first on Wall Street to initiate coverage on the stock. Explore NRXS' promising growth prospects and financial health amid market challenges.
Neutral
GlobeNewsWire
3 months ago
NeurAxis to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024
CARMEL, Ind., Sept. 19, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will participate in a webcasted presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2024 Investor Conference, taking place virtually on Tuesday, October 1, 2024.
Neutral
GlobeNewsWire
3 months ago
NeurAxis Announces Geisinger Health Plan Medical Policy Coverage for PENFS, Effective September 15 2024
CARMEL, Ind., Aug. 27, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), for Geisinger Health Plan, serving 600,000+ enrollees in central Pennsylvania. This medical policy will bring our national total coverage for PENFS to roughly 24 million insured lives, with more decisions from major payers still pending.
Neutral
GlobeNewsWire
4 months ago
NeurAxis Announces BCBS of Vermont Medical Policy Coverage for PENFS, effective October 1st 2024
CARMEL, Ind., Aug. 13, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), for Blue Cross Blue Shield (BCBS) of Vermont Medical Members, effective 10/1/2024. This medical policy will bring our national total coverage for PENFS to roughly 23 million, with more decisions from major payers still pending.
Neutral
Seeking Alpha
4 months ago
NeurAxis, Inc. (NRXS) Q2 2024 Earnings Call Transcript
NeurAxis, Inc. (NYSE:NRXS ) Q2 2024 Earnings Conference Call August 9, 2024 9:00 AM ET Company Participants Ben Shamsian - Investor Relations Brian Carrico - Chief Executive Officer Tim Henrichs - Chief Financial Officer Conference Call Participants Mark Foster - Kirr Marbach & Co Operator Good day and thank you for standing by. Welcome to NeurAxis Reports Second Quarter 2024 Financial Results.
Neutral
GlobeNewsWire
4 months ago
NeurAxis Reports Second Quarter 2024 Financial Results
Carmel, Ind., Aug. 09, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the second quarter period ended June 30, 2024.
Charts implemented using Lightweight Charts™